Sonoma Pharmaceuticals Files 8-K on Shareholder Votes

TL;DR

Sonoma Pharma (SNOA) filed an 8-K on shareholder votes. Keep an eye on outcomes.

AI Summary

Sonoma Pharmaceuticals, Inc. filed an 8-K on August 29, 2025, reporting on matters submitted to a vote of security holders as of August 27, 2025. The filing details the company's corporate information, including its address in Boulder, CO, and its former name, Oculus Innovative Sciences, Inc., which was changed on June 22, 2006.

Why It Matters

This filing indicates that Sonoma Pharmaceuticals held a vote of its security holders, which could pertain to significant corporate decisions or changes that may impact the company's future direction.

Risk Assessment

Risk Level: low — The filing is a routine corporate disclosure regarding a vote of security holders and does not contain immediate financial or operational risks.

Key Players & Entities

• Sonoma Pharmaceuticals, Inc. (company) — Registrant
• August 27, 2025 (date) — Earliest event date
• August 29, 2025 (date) — Filing date
• Boulder, CO (location) — Principal executive offices address
• Oculus Innovative Sciences, Inc. (company) — Former company name

FAQ

Filing Documents

• sonoma_8k.htm (8-K) — 36KB
• 0001683168-25-006580.txt ( ) — 197KB
• snoa-20250827.xsd (EX-101.SCH) — 3KB
• snoa-20250827_lab.xml (EX-101.LAB) — 33KB
• snoa-20250827_pre.xml (EX-101.PRE) — 22KB
• sonoma_8k_htm.xml (XML) — 4KB

07

Item 5.07. Submission of Matters to a Vote of Security Holders. Our annual meeting of stockholders was held on August 27, 2025. Proxies were solicited pursuant to our definitive proxy statement filed on July 11, 2025 with the Securities and Exchange Commission under Section 14(a) of the Securities Exchange Act of 1934. The number of shares of the Company's common stock entitled to vote at the annual meeting was 1,642,765. The number of shares of common stock present or represented by valid proxy at the annual meeting was 718,469. Each share of common stock was entitled to one vote with respect to matters submitted to the Company's stockholders at the annual meeting. At the annual meeting, our stockholders voted on the matters set forth below. Proposal 1 – Election of Class II Director Dr. Jay Birnbaum was duly elected as our Class II director. The results of the election were as follows: NOMINEE FOR WITHHELD Jay Birnbaum 123,034 19,478 Proposal 2 – Advisory Vote to Approve Executive Compensation Our stockholders voted upon and approved, by non-binding advisory vote, the compensation of our named executive officers for the year ended March 31, 2025, as described in our proxy statement dated July 11, 2025. The votes on this proposal were as follows: FOR AGAINST ABSTAIN 112,548 26,360 3,604 Proposal 3 – Ratification of the Appointment of Independent Registered Public Accounting Firm Our stockholders voted upon and approved the ratification of the appointment of Frazier & Deeter, LLC as our independent registered public accounting firm for the fiscal year ending March 31, 2026. The votes on this proposal were as follows: FOR AGAINST ABSTAIN 702,484 13,569 2,416 Proposal 4 – Adjournment to Solicit Additional Proxies Our stockholders voted upon and approved a proposal to authorize the adjournment of the meeting to permit further solicitation of proxies, if necessary or appropriate, if sufficient votes are not represented at the meet

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SONOMA PHARMACEUTICALS, INC. Date: August 29, 2025 By: /s/ Amy Trombly Name: Title: Amy Trombly Chief Executive Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR